Search research articles
Contact Us
Filters
Showing results (1301-1310 of 1,388) with videos related to
Page
of 139
Sort By:
Journal for Immunotherapy of Cancer
|
October 9, 2021
Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)
Peter Kar Han Lau, Breon Feran, Lorey Smith, et al.
Nature Immunology
|
May 20, 2020
Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity
Junyun Lai, Sherly Mardiana, Imran G House, et al.
Trials
|
April 2, 2021
The effects of different doses of exercise on pancreatic β-cell function in patients with newly diagnosed type 2 diabetes: study protocol for and rationale behind the "DOSE-EX" multi-arm parallel-group randomised clinical trial
Mark P P Lyngbaek, Grit E Legaard, Sebastian L Bennetsen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 2023
Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial
Daniel S W Tan, Enriqueta Felip, Gilberto de Castro, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 10, 2024
Capmatinib plus nazartinib in patients with EGFR-mutated non-small cell lung cancer
Enriqueta Felip, Giulio Metro, Ross A Soo, et al.
Nature Metabolism
|
May 1, 2023
Effects of different doses of exercise and diet-induced weight loss on beta-cell function in type 2 diabetes (DOSE-EX): a randomized clinical trial
Grit E Legaard, Mark P P Lyngbæk, Thomas P Almdal, et al.
The New England Journal of Medicine
|
June 4, 2013
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer
Alice T Shaw, Dong-Wan Kim, Kazuhiko Nakagawa, et al.
The Lancet. Oncology
|
November 11, 2018
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
Benjamin J Solomon, Benjamin Besse, Todd M Bauer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 29, 2019
Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors
M D Hellmann, T-W Kim, C B Lee, et al.
Chest
|
December 27, 2019
IgA Antibodies Directed Against Citrullinated Protein Antigens Are Elevated in Patients With Idiopathic Pulmonary Fibrosis
Joshua J Solomon, Scott Matson, Lindsay B Kelmenson, et al.
Page
of 139
Search research articles
Search
Showing results (1301-1310 of 1,388) with videos related to
Sort By:
Page
of 139
Journal for Immunotherapy of Cancer
|
October 9, 2021
Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)
Peter Kar Han Lau, Breon Feran, Lorey Smith, et al.
Nature Immunology
|
May 20, 2020
Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity
Junyun Lai, Sherly Mardiana, Imran G House, et al.
Trials
|
April 2, 2021
The effects of different doses of exercise on pancreatic β-cell function in patients with newly diagnosed type 2 diabetes: study protocol for and rationale behind the "DOSE-EX" multi-arm parallel-group randomised clinical trial
Mark P P Lyngbaek, Grit E Legaard, Sebastian L Bennetsen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 2023
Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial
Daniel S W Tan, Enriqueta Felip, Gilberto de Castro, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 10, 2024
Capmatinib plus nazartinib in patients with EGFR-mutated non-small cell lung cancer
Enriqueta Felip, Giulio Metro, Ross A Soo, et al.
Nature Metabolism
|
May 1, 2023
Effects of different doses of exercise and diet-induced weight loss on beta-cell function in type 2 diabetes (DOSE-EX): a randomized clinical trial
Grit E Legaard, Mark P P Lyngbæk, Thomas P Almdal, et al.
The New England Journal of Medicine
|
June 4, 2013
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer
Alice T Shaw, Dong-Wan Kim, Kazuhiko Nakagawa, et al.
The Lancet. Oncology
|
November 11, 2018
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
Benjamin J Solomon, Benjamin Besse, Todd M Bauer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 29, 2019
Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors
M D Hellmann, T-W Kim, C B Lee, et al.
Chest
|
December 27, 2019
IgA Antibodies Directed Against Citrullinated Protein Antigens Are Elevated in Patients With Idiopathic Pulmonary Fibrosis
Joshua J Solomon, Scott Matson, Lindsay B Kelmenson, et al.
Page
of 139